Influx transporter variants as predictors of cancer chemotherapy-induced toxicity: systematic review and meta-analysis. (July 2016)

• Record Type: Journal Article
• Authors: Zaïr, Zoulikha M; Singer, Donald RJ
• Is Part Of: Pharmacogenomics. Volume 17:Number 10(2016)
• Page Start: 1189
• Page End: 1205
• Publication Date: 2016-07
• Subjects: adverse drug reaction -- chemotherapy -- drug influx transporter -- meta-analysis -- SLC19A1 lung cancer -- SLCO1B1 -- systematic review; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2015-0005
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: Chemotherapeutic agents have been shown to increase lung patient survival, however their use may be limited by their serious adverse effects. We aimed to assess int impact of pharmacogenetic variation of influx transporters on inter-individual patient variation in adverse drug reactions.Patients & methods: We conducted a meta-analysis and systemic review and identified 16 publications, totaling 1510 patients, to be eligible for review.Results: Meta-analysis showed east-Asian patients expressing SLCO1B1 521T>C or 1118G>A to have a two- to fourfold increased risk of irinotecan-induced neutropenia but not diarrhea. American patients, expressing SLC19A1 IVS2(4935) G>A, were further associated with pemetrexed/gemcitabine-induced grade 3+ leukopenia.Conclusion: Future studies should look to robust validation of SLCO1B1 and SLC19A1 as prognostic markers in the management of lung cancer patients.